GSK’s Promacta Adds ‘Breakthrough’ Claim On Strength Of Small NIH Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Supplemental approval for severe aplastic anemia, a “breakthrough” designation, was based on a single-center, open-label Phase II trial in 43 patients that was conducted by the National Heart, Lung and Blood Institute.